Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Hepatol. May 27, 2023; 15(5): 688-698
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.688
Table 2 Diagnosis and background of the studied groups, n (%)
Group

Variables
GTMI (n = 21)
CG (n = 20)
Total (n = 41)
P value
Diagnostics
Liver metastasis9 (42.9)8 (40.0)17 (41.5)
Hepatocellular carcinoma8 (38.1)3 (15.0)11 (26.8)
Hepatic nodule3 (14.3)4 (20.0)7 (17.1)
Cholangiocarcinoma1 (4.8)4 (20.0)5 (12.2)
Hemangioma0 (0.0)1 (5.0)1 (2.4)-
Background
Hepatic cirrhosis
No15 (71.4)18 (90.0)33 (80.5)
Yes6 (28.6)2 (10.0)8 (19.5)0.23792
Hepatitis C
No17 (81.0)18 (90.0)35 (85.4)
Yes4 (19.0)2 (10.0)6 (14.6)0.66282
Previous neoplasm
No10 (47.6)8 (40.0)18 (43.9)
Yes11 (52.4)12 (60.0)23 (56.1)0.62321
Chemotherapy
No12 (57.1)13 (65.0)25 (61.0)
Yes9 (42.9)7 (35.0)16 (39.0)0.60621
Smoker/former smoker
No15 (71.4)18 (90.0)33 (80.5)
Yes6 (28.6)2 (10.0)8 (19.5)0.23792